drugset / Trial / NCT03392051

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel

NCT03392051

Phase 1 Completed 18 enrolled Akcea Therapeutics
Non-randomizedSequentialOpen-labelOther

Summary

This is a single center, open label, single sequence, two treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of multiple doses of clopidogrel

Timeline

Start
2017-12-28
Primary completion
2018-03-18
Completion
2018-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg Oral
Subject Pelacarsen Antisense oligonucleotide Subcutaneous